NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
Clinical Trials
18 trialsNCT01407198 2025-12-19
Nilotinib With Radiation for High Risk Chordoma
Massachusetts General Hospital
Phase 1 Completed
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00976612 2020-01-07
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
Asan Medical Center
Completed
NCT00633295 2017-06-22
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Novartis
Phase 2 Completed
NCT01110668 2017-02-28
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00718562 2017-02-23
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
Novartis
Phase 2 Completed
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT02587169 2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2 Unknown
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT00441155 2013-05-13
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Phase 1 Completed
NCT00782834 2013-04-22
07060
Fox Chase Cancer Center
Phase 2 Terminated
NCT01270893 2012-08-02
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed